|
Mar 4
|
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer
|
|
Feb 28
|
Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues
|
|
Jan 8
|
Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?
|
|
Jan 4
|
Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo
|
|
Jan 3
|
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
|
|
Dec 22
|
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
|
|
Dec 18
|
Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes
|
|
Nov 27
|
Japan panel recommends approval of updated Daiichi Sankyo COVID shot- Kyodo
|
|
Nov 9
|
VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML
|
|
Sep 11
|
ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial
|
|
Sep 10
|
Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial
|
|
Sep 10
|
Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer in HERTHENA-Lung01 Phase 2 Trial
|
|
Sep 7
|
DS-3939 Enters Clinical Development in Patients Across Several Types of Advanced Solid Cancers
|
|
Jul 3
|
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
|